治疗成人失眠症的双重食欲素受体拮抗剂daridorexant

Dual orexin receptor antagonist daridorexant for the treatment of adults with insomnia

daridorexant是一种双重食欲素受体拮抗剂(dual orexin receptor antagonist,DORA),于2022年1月10日被美国FDA批准上市(商品名:Quviviq),用于治疗以入睡困难和/或睡眠维持困难为特征的失眠症成人患者。与传统镇静类催眠药物不同,daridorexant通过与双重食欲素受体的特异性结合抑制觉醒食欲素神经肽的作用。本文对其作用机制、药效学、药动学、安全性及临床研究进行综述。

Daridorexant is a dual orexin receptor antagonist(DORA),which was approved by the U.S.FDA on January 10,2022(trade name:Quviviq)for the treatment of adults with insomnia,characterized by diffculties with sleep onset and/or sleep maintenance.Unlike traditional sedative-hypnotic drugs,daridorexant inhibits the actions of the wake-promoting orexin neuropeptides,by specific binding to both orexin receptor.In this paper,the mechanism of action,pharmacodynamics,pharmacokinetics,safety,and clinical research of daridorexant are reviewed.